[Skip to Content]
[Skip to Content Landing]
Citations 0
Letters
January 21, 1998

Integrin β3 Blockade With Abciximab and Protection From Myocardial Ischemic Events

Author Affiliations
 

Margaret A.WinkerMD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Senior EditorIndividualAuthor

JAMA. 1998;279(3):195-196. doi:10.1001/jama.279.3.193

To the Editor.—As reported by Dr Topol and colleagues1 and Drs Fischman and Savage,2 the mechanism by which the blockage of β3 integrin with abciximab results in improved cardiac preservation is unclear. We suggest a possibility not mentioned in their speculations: β3 integrin was shown to be a mediator in the transport of iron into cells independent of transferrin. Therefore, blockage of β3 integrin might be expected to reduce intracellular concentrations of iron.3,4 Iron mediates free radical formation and reperfusion injury. Iron chelators such as desferrioxamine, which diminish iron transport into cells, have a protective effect on cardiac damage during reperfusion5 and may be analogous to the use of substances that impair uptake of iron into cells by β3 integrin. Protection of the cell from exposure to iron may be an important factor in the beneficial results of β3 integrin blockage as reported by Topol et al.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×